Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AtriCure, Inc.ATRC · Entity 2704 | Director · President, CEO, & Director | July 30, 2026 | August 03, 2026 |
| Axonics, Inc.AXNX · Entity 86004 | Director | November 15, 2024 | November 15, 2024 |
| Inspire Medical Systems, Inc.INSP · Entity 1186 | Director | July 20, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AtriCure, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 774,434 |
Ending reported balance
After 2026-07-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-30 · Gift · Disposed 700 · Balance 778,434 F1: No consideration was received in connection with this gift to the reporting person's parent. Row 2 · 2026-07-30 · Gift · Disposed 4,000 · Balance 774,434 F2: No consideration was received in connection with this charitable gift. |
| Common StockSEC Table I · non-derivative | IndirectHeld by reporting person's children | 14,310 |
Reported balance
Holding disclosure · report date 2026-07-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 14,310 F3: The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectHeld by reporting person's parent | 2,950 |
Reported balance
Holding disclosure · report date 2026-07-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,950 F3: The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectHeld by reporting person's sibling | 1,000 |
Reported balance
Holding disclosure · report date 2026-07-30 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,000 F3: The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: No consideration was received in connection with this gift to the reporting person's parent.
F2: No consideration was received in connection with this charitable gift.
F3: The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.
Axonics, Inc.
Report date November 15, 2024 · Filed November 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 1
1 source rowRow 1 · 2024-11-15 · Disposition to issuer · Disposed 17,861 · Balance 0 F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (the "Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.10 · Expires 2029-08-22 | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-15 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.85 · Expires 2029-02-27 | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (the "Merger Consideration").
F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.
Inspire Medical Systems, Inc.
Report date July 20, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,631 |
Reported balance
After 2026-07-20 transaction · row 1
1 source rowRow 1 · 2026-07-20 · Grant · Acquired 5,631 · Balance 5,631 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in three equal annual installments on the first three anniversaries of the date of grant, subject to the Reporting Person's continued service on the board of directors of the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in three equal annual installments on the first three anniversaries of the date of grant, subject to the Reporting Person's continued service on the board of directors of the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2021 Filed Jul 2, 2021 20:16 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 251 | $45.72 | $11,475.72 |
DisclosureSEC source: 0001209191-21-044946 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,541 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021, which was the first trading day of the applicable offering period. The closing price on January 4, 2021 was $53.79. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:17 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 55,241 | $66.31 | $3,663,030.71 |
DisclosureSEC source: 0001209191-21-017211 · doc4.xml · nonDerivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,290 F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:17 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 20,358 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017211 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,531 F2 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:17 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 29,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017211 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,173 F1 · price: The Reporting person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2014 Equity Incentive Plan. The award had both a Company performance goal and a service period requirement, which were both met. Read SEC document |
| February 12, 2021 Filed Feb 12, 2021 21:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-21-010164 · doc4.xml · derivative · entry 9 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F4 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on January 24, 2014 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| February 12, 2021 Filed Feb 12, 2021 21:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $65.00 | $1,625,000.00 |
DisclosureSEC source: 0001209191-21-010164 · doc4.xml · nonDerivative · entry 6 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,795 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| February 12, 2021 Filed Feb 12, 2021 21:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $21.04 | $526,000.00 |
DisclosureSEC source: 0001209191-21-010164 · doc4.xml · nonDerivative · entry 5 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-21-010164 · doc4.xml · derivative · entry 8 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F4 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on January 24, 2014 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $64.00 | $1,600,000.00 |
DisclosureSEC source: 0001209191-21-010164 · doc4.xml · nonDerivative · entry 4 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,795 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $21.04 | $526,000.00 |
DisclosureSEC source: 0001209191-21-010164 · doc4.xml · nonDerivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-21-010164 · doc4.xml · derivative · entry 7 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F4 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on January 24, 2014 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $63.00 | $1,575,000.00 |
DisclosureSEC source: 0001209191-21-010164 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,795 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.00 to $63.05 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:30 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $21.04 | $526,000.00 |
DisclosureSEC source: 0001209191-21-010164 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 13:52 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-21-009141 · doc4.xml · derivative · entry 6 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on January 24, 2014 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 13:52 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $62.00 | $1,550,000.00 |
DisclosureSEC source: 0001209191-21-009141 · doc4.xml · nonDerivative · entry 4 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,795 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 13:52 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $21.04 | $526,000.00 |
DisclosureSEC source: 0001209191-21-009141 · doc4.xml · nonDerivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 13:52 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-21-009141 · doc4.xml · derivative · entry 5 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 25,000 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on January 24, 2014 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 13:52 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $61.00 | $1,525,000.00 |
DisclosureSEC source: 0001209191-21-009141 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,795 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 13:52 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $21.04 | $526,000.00 |
DisclosureSEC source: 0001209191-21-009141 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 14:03 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-21-007651 · doc4.xml · derivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 25,000 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on January 24, 2014 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 14:03 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $60.00 | $1,500,000.00 |
DisclosureSEC source: 0001209191-21-007651 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,795 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 14:03 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $21.04 | $526,000.00 |
DisclosureSEC source: 0001209191-21-007651 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:27 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-21-003426 · doc4.xml · derivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 25,000 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on January 24, 2014 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:27 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $59.00 | $1,475,000.00 |
DisclosureSEC source: 0001209191-21-003426 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,795 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:27 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $21.04 | $526,000.00 |
DisclosureSEC source: 0001209191-21-003426 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 13:17 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 291 | $38.48 | $11,197.68 |
DisclosureSEC source: 0001209191-21-000007 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,795 F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended December 31, 2020. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 1, 2020, which was the first trading day of the applicable offering period. The closing price on July 1, 2020 was $45.27. Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 01:09 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to buy) · Derivative | 24,953 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-20-065274 · doc4.xml · derivative · entry 6 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 24,953 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on January 24, 2014 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 01:09 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 24,953 | $58.00 | $1,447,274.00 |
DisclosureSEC source: 0001209191-20-065274 · doc4.xml · nonDerivative · entry 4 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,504 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 01:09 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 24,953 | $21.04 | $525,011.12 |
DisclosureSEC source: 0001209191-20-065274 · doc4.xml · nonDerivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 01:09 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-20-065274 · doc4.xml · derivative · entry 5 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,953 Underlying: Common Stock · 47 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on January 24, 2014 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 01:09 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 47 | $58.00 | $2,726.00 |
DisclosureSEC source: 0001209191-20-065274 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,504 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| December 23, 2020 Filed Dec 29, 2020 01:09 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 47 | $21.04 | $988.88 |
DisclosureSEC source: 0001209191-20-065274 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-20-065015 · doc4.xml · derivative · entry 9 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 25,000 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F4 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on January 24, 2014 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-20-065015 · doc4.xml · derivative · entry 8 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: These options were granted on January 24, 2014. The options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $57.00 | $1,425,000.00 |
DisclosureSEC source: 0001209191-20-065015 · doc4.xml · nonDerivative · entry 6 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,504 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $21.04 | $526,000.00 |
DisclosureSEC source: 0001209191-20-065015 · doc4.xml · nonDerivative · entry 5 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $56.00 | $1,400,000.00 |
DisclosureSEC source: 0001209191-20-065015 · doc4.xml · nonDerivative · entry 4 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,504 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 21:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $21.04 | $526,000.00 |
DisclosureSEC source: 0001209191-20-065015 · doc4.xml · nonDerivative · entry 3 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,751 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-20-065015 · doc4.xml · derivative · entry 7 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 24,751 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: These options were granted on January 24, 2014. The options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 24,751 | $55.00 | $1,361,305.00 |
DisclosureSEC source: 0001209191-20-065015 · doc4.xml · nonDerivative · entry 2 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,504 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 24,751 | $21.04 | $520,761.04 |
DisclosureSEC source: 0001209191-20-065015 · doc4.xml · nonDerivative · entry 1 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,249 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · derivative · entry 12 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,751 Underlying: Common Stock · 50,249 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F5 · derivative.exercise_date: These options were granted on January 24, 2014. The options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 50,249 | $53.51 | $2,688,823.99 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · nonDerivative · entry 8 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,504 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $53.00 to $55.00 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 50,249 | $21.04 | $1,057,238.96 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · nonDerivative · entry 7 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · derivative · entry 11 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 25,000 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F5 · derivative.exercise_date: These options were granted on January 24, 2014. The options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · derivative · entry 10 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F4 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on November 1, 2012 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of the common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · derivative · entry 9 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. F4 · derivative.exercise_date: Options to purchase shares in 25,000 increments were granted on November 1, 2012 and vest at each Option Trigger Event. "Option Trigger Event" shall mean the volume adjusted weighted average closing price of the common stock of the Company as reported by NASDAQ (or any other exchange on which the common stock of the Company is listed) for 30 consecutive days equals or exceeds each of $10.00 per share, $12.50 per share, $15.00 per share, $17.50 per share, $20.00 per share, $25.00 per share, $30.00 per share, $35.00 per share and $40.00 per share. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $52.00 | $1,300,000.00 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · nonDerivative · entry 6 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,504 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 25,000 | $21.04 | $526,000.00 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · nonDerivative · entry 5 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 22:07 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 25,000 | $51.00 | $1,275,000.00 |
DisclosureSEC source: 0001209191-20-064677 · doc4.xml · nonDerivative · entry 4 CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,504 F2 · shares: These shares were sold pursuant to a 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.